Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

G R Hudes; F Nathan; C Khater; N Haas; M Cornfield; B Giantonio; R Greenberg; L Gomella; S Litwin; E Ross

doi:10.1200/JCO.1997.15.9.3156

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

Identifier:nobleid.org/w1/20260515/EB3DBCBD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/EB3DBCBD.svg?ark=w1%2F20260515%2FEB3DBCBD)](https://nobleid.org/work/w1/20260515/EB3DBCBD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

Identifier:nobleid.org/w1/20260515/EB3DBCBD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/EB3DBCBD.svg?ark=w1%2F20260515%2FEB3DBCBD)](https://nobleid.org/work/w1/20260515/EB3DBCBD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work